Dr. Acharya is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
269-01 76th Ave
Suite 255
New Hyde Park, NY 11040Phone+1 718-470-3460Fax+1 718-343-4642
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1996 - 1999
- Westchester Medical CenterResidency, Pediatrics, 1993 - 1995
- Seth G.S. Medical CollegeClass of 1985
Certifications & Licensure
- NY State Medical License 1996 - 2026
- CT State Medical License 2006 - 2007
- NJ State Medical License 2007 - 2007
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease Start of enrollment: 2005 Sep 01
- Evaluation of the Duration of Therapy for Thrombosis in Children Start of enrollment: 2008 Mar 01
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors Start of enrollment: 2021 Jun 28
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 95 citationsAnnexin A2 Promotes Glioma Cell Invasion and Tumor ProgressionHaiyan Zhai, Suchitra S. Acharya, Iordanis Gravanis, Saira Mehmood, Roberta J. Seidman
The Journal of Neuroscience. 2011-10-05 - 162 citationsRare inherited disorders of fibrinogenS. S. Acharya, Donna DiMichele
Haemophilia. 2008-11-01 - 26 citationsManagement of Rare Coagulation Disorders in 2018Shilpa Jain, Suchitra S. Acharya
Transfusion and Apheresis Science. 2018-12-01
Abstracts/Posters
- Assessment of Provider Practices Regarding Management of VTE in Pediatric LeukemiaSuchitra Acharya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Provider Practices Regarding Prophylactic Anticoagulation in Children with LeukemiaSuchitra Acharya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- Marstacimab Gets FDA Nod for Hemophilia a or B Without InhibitorsOctober 11th, 2024
- FDA Approves First Once-Weekly Drug Treatment Regimen for HemophiliaOctober 11th, 2024
- U.S. FDA Approves Pfizer’s HYMPAVZI™ (Marstacimab-Hncq) for the Treatment of Adults and Adolescents with Hemophilia a or B Without InhibitorsOctober 11th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: